Invasive disease owing to group B Streptococcus (GBS) remains an important cause of illness and death among infants younger than 90 days in the United States, despite declines in early-onset disease (EOD; with onset at 0-6 days of life) that are attributed to intrapartum antibiotic prophylaxis (IAP). Maternal vaccines to prevent infant GBS disease are currently under development.
G roup B Streptococcus (GBS) remains a leading infectious cause of morbidity and mortality among infants in the United States 1 despite marked declines in disease during the first week of life (early-onset disease [EOD] ) through widespread implementation of guidelines for intrapartum antibiotic prophylaxis (IAP). [2] [3] [4] [5] [6] Of the EOD cases that occur in the United States annually, a portion may be preventable by improved implementation of existing IAP guidelines. 7 However, GBS disease among infants aged 7 to 89 days (lateonset disease [LOD] ) is not prevented by IAP. 8 Moreover, more than 30% of infants delivered in the United States are now exposed to intrapartum antibiotics, raising concern about potential for emergence of antibiotic resistance in GBS or other neonatal pathogens, as well as unintended consequences from disruption of the establishment of the newborn microbiota.
9-12
Maternal immunization represents a nonantibiotic strategy to prevent both EOD and LOD. Multivalent polysaccharideprotein conjugate vaccines are under development against GBS capsular types, with candidate vaccines in phase I and II trials. 13, 14 To guide refinement of current perinatal GBS disease prevention approaches and vaccine development, we analyzed data from a multistate surveillance system capturing approximately 10% of US live births to describe EOD and LOD epidemiology, incidence trends, and associated GBS strain characteristics. We also describe potential gaps in implementation of existing IAP guidelines among EOD cases.
Methods

Surveillance
Active Bacterial Core surveillance (ABCs) conducts active, population-based and laboratory-based surveillance for invasive GBS disease among infants in select counties of 10 states across the United States. 15, 16 In 2015, it included an area with 439 151 live births. From 2006 to 2015, GBS surveillance was consistent in San Francisco, California (3 counties); Denver, Colorado (5 counties); Atlanta, Georgia (20 counties); Portland, Oregon (3 counties); Rochester and Albany, New York (15 counties); multiple urban areas in Tennessee (11 counties) ; and the entire states of Connecticut, Maryland, Minnesota, and New Mexico. The staff of ABCs contacted laboratories serving surveillance area residents for ascertainment of GBS culture-positive cases. Standardized case report forms capturing clinical data, epidemiological data, and intrapartum history, including administration of recommended IAP antibiotics (penicillin, ampicillin, cefazolin, clindamycin, or vancomycin) , were completed through review of medical and maternal labor and delivery records. The methods of ABCs, including those used for the identification of clinical syndromes, determination of race, and ascertainment of death as a hospitalization outcome are detailed elsewhere.
5,17
Ethical Considerations
The ABCs case reporting and isolate collection were reviewed in accordance with Centers for Disease Control and Prevention human research protection procedures and were determined to be nonresearch public health surveillance. The ABCs sites reviewed the protocol and obtained institutional review board approval where required.
Definitions
An invasive case was defined as isolation of GBS from a normally sterile site from a surveillance area resident. Infants born at 37 or more completed weeks' gestation were categorized as being born full term.
Considerations for Vaccine Protection Based on Gestational Age and Age at Disease Onset
Transplacental transfer of maternal antibodies peaks after 32 to 33 weeks' gestation, and transferred antibodies then steadily decline after birth as the infant ages. 18 Efficacy of a maternal vaccine might therefore be lower in preventing GBS disease in infants born preterm, particularly before peak antibody transfer, and/or infants with disease onset more than 42 days after birth (which is the half-life of anti-GBS IgG in infants 19 ).
18,20
Therefore, for this analysis, we compared characteristics of cases in infants born at less than 35 weeks' gestation or with disease onset after 42 days of life with those born at 35 or more weeks' gestation or with disease onset within the first 42 days of life.
Specimen Collection and Testing
During the study period, 7 sites (in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon) collected isolates. All serotyping and antimicrobial susceptibility testing were done at the US Centers for Disease Control and Prevention Streptococcus laboratory, except for susceptibility testing for isolates from Minnesota, which were tested at the Minnesota Department of Public Health. Isolates were serotyped by latex agglutination test using rabbit antisera to capsular polysaccharide types Ia, Ib, and II through IX. Meaning Despite reductions in EOD, a significant burden of invasive GBS disease among infants remains; an effective multivalent maternal vaccine could reduce disease burden.
ning in 2011, macrolide-inducible clindamycin resistance was determined using the erythromycin-clindamycin combinationwell broth dilution method. 23, 24 For isolates from 2015, wholegenome sequencing data were available and analyzed using a validated bioinformatics pipeline for assessment of antimicrobial resistance phenotypes, multilocus sequence typing (https://pubmlst.org/sagalactiae/), and capsular serotypes.
25
Statistical Analysis
We calculated incidence rates using ABCs case counts as the numerator and the number of live births as the denominator. We used state vital records and national vital statistics reports to obtain ABCs site-specific live birth data. Linear trends in incidence rates were evaluated using the CochranArmitage test. For incidence rates that had a statistically significant departure from linearity, trends were assessed using the nonparametric Mann-Kendall test. A P value less than .05 was considered statistically significant, and χ 2 tests were used to compare distributions of categorical variables. Data were analyzed using SAS version 9.4 (SAS Institute Inc). National estimates of cases were obtained by applying the age and racial distribution of the US population in 2015 to the race-and-agespecific rates obtained from the ABCs surveillance areas. Data were analyzed from December 2017 to April 2018.
Results
Description of GBS Cases
We identified 1277 cases of EOD from 2006 to 2015 across the surveillance areas ( 
Trends in EOD
From 2006 to 2015, EOD incidence declined overall (from 0.37 to 0.23 per 1000 live births; P < .001; Figure 1 ) and when stratified by gestational age (in full-term infants, from 0.30 to 0.17 per 1000 live births; P < .001; in preterm infants, from 0.84 to 0.63 per 1000 live births; P = .002; Figure 1 ). From 2006 to 2015, annual EOD rates were higher among preterm infants than full-term infants (mean [range] rate ratio, 3.0 [2.0-3.8] times) and black infants compared with white infants (mean [range] rate ratio, 2.4 [1.6-3.7] times). There was a statistically significant decline in EOD among white infants (from 0.29 to 0.15 per 1000 live births; P < .001) and black infants (from 0.76 to 0.55 per 1000 live births; P = .04). a Total of proportions could be more than 100% because some cases had isolates from more than 1 source.
b Total of proportions could be more than 100% because some cases had more than 1 syndrome identified; no other syndrome overlapped with bacteremia without focus.
Missed Opportunities for Prevention of EOD Under Current IAP-Based Prevention Guidelines
Overall, 617 mothers of 1277 infants with EOD (48.3%) had no indication for and did not receive IAP, and 278 of 1277 mothers (21.8%) failed to receive IAP despite an indication of need ( Figure 2 ). Among the mothers of infants with EOD who received a recommended IAP antibiotic, an incorrect agent was common among those with penicillin allergy but no history of associated anaphylaxis, angioedema, respiratory distress, or urticaria; 55 of 57 (96%) received clindamycin instead of cefazolin. 4 Among 322 cases of EOD with adequate data to evaluate duration of antibiotic exposure, 196 mothers (60.9%) had received IAP for 4 or more hours before delivery; of these, 107 cases of EOD were in newborns whose mothers were admitted to the hospital 5 or more hours before delivery and would have had an opportunity to receive IAP for an adequate duration. Among mothers of infants with EOD who did not receive IAP and had no indication of need, 512 of 617 (83.0%) had negative GBS screening test results; among those who did not receive IAP and had an indication of need, unknown GBS status and presence of a clinical risk factor was the most common scenario (135 of 278 mothers [48.6%]). Thirteen cases of EOD occurred among infants whose mothers had no indication for IAP and underwent cesarean delivery before onset of labor and rupture of membranes.
Trends in LOD
The incidence of LOD remained stable overall (mean, 0.31 per 1000 live births) and when stratified by gestational age at delivery or race (Figure 1 ). From 2006 to 2015, annual LOD rates were higher among preterm infants compared with term infants (mean [range] rate ratio, 6.4 [3.7-7.7 ] times) and black infants compared with white infants (mean [range] rate ratio, 2.9 [1.9-4.4] times).
Serotypes and Antimicrobial Susceptibility
Among sites that collected isolates, serotype data were available for 887 of 959 cases of EOD (92.5%) and 856 of 938 cases of LOD (91.3%). Antimicrobial susceptibility data were available for 877 of 959 cases of EOD (91.5%) and 850 of 938 cases of LOD (90.6%). stead of clindamycin, a less effective agent with increasing rates of nonsusceptibility. 31 We identified extremely few cases occurring in infants born to mothers who underwent cesarean delivery before onset of labor and rupture of membranes, which supports the current recommendation of not requiring IAP administration to such mothers. 4 Cerebrospinal fluid was the sole source for GBS isolation in 11 infants with EOD; current guidelines recommend lumbar puncture for newborns with signs of sepsis if the infant is stable enough to tolerate the procedure.
4
While revisions to existing guidelines may further clarify and address persistent areas of challenge, an alternative strategy, such as prevention through vaccines, will likely be necessary for further significant declines in disease rates. Although overall LOD rates were stable over the study period, serotype-specific incidence varied more in LOD than EOD, with a notable increase in LOD owing to serotype III; 2015 whole-genome sequencing data showed that 78.2% of these isolates possessed the HvgA gene, which is found mostly in the globally dominant multilocus sequence type ST17.
32-34 Both
England and the Netherlands have reported recent increases in LOD 32, 35 ; in the Netherlands, this increase was associated with expansion of a particular subclade of ST17, and it will be important to monitor for this expansion elsewhere.
36
Overall, more than 99% of disease was owing to 6 leading serotypes, suggesting that a hexavalent vaccine against these serotypes will cover almost all cases. A recent decisionanalysis model of potential GBS prevention strategies in the United States 30 identified maternal immunization in conjunction with IAP, as indicated by current guidelines for unvaccinated women, as a strategy that could prevent more disease than universal screening and IAP do for a similar cost per quality-adjusted life-year. Recommendations for influenza and tetanus, diphtheria, and acellular pertussis vaccines during pregnancy have helped improve acceptability and implementation capacity for vaccination during pregnancy, and survey data suggest support among US obstetricians for a safe and efficacious maternal GBS vaccine. [37] [38] [39] However, 20.4% of EOD and 49.6% of LOD cases were among infants who were born at less than 35 weeks' gestational age and/or experienced disease onset at more than 42 days of life, and maternal vaccination might be less effective at preventing these cases. To help prevent GBS cases among preterm infants and LOD with onset beyond 42 days of life, strategies that include requirement for higher vaccine immunogenicity for serotypes Ia, II, IV, and V, which were overrepresented among these cases, may be needed.
Limitations
While ABCs is a stable surveillance system that captures invasive GBS cases from over 400 000 live births annually, it represents only 10% of US live births and may not reflect the full variation within the country. Additionally, we had only 1 year of whole-genome sequencing data and were unable to correlate disease patterns over time with changes in strain characteristics at the genomic level. Information on missed opportunities for prevention of EOD was limited to data available in the labor and delivery record and was only available for cases with no comparison group; population-level data are needed to characterize GBS prevention guideline implementation practices.
Conclusions
Despite significant declines in EOD rates attributed to IAP, the burden of EOD and LOD in the United States remains substantial. Refinements to existing IAP guidelines could improve guideline adherence and sustain current low rates of EOD. Continued microbiological surveillance for emergence of β-lactam nonsusceptibility, increasing clindamycin resistance and expansion of virulent clones such as serotype III ST17 strains, remain critical for early identification of emerging threats to the effectiveness of treatment and prevention strategies. With LOD rates higher than EOD rates, greater than half of all infant GBS disease in the United States currently is not preventable by any currently available strategy. A safe and efficacious maternal vaccine against the most common serotypes holds promise to prevent a substantial portion of this remaining burden. With candidate vaccines in advanced stages of development, surveillance to monitor disease trends and characteristics provides a key evidence base for vaccine and public health policy decisions. 
